HRP20131088T1 - Äśvrsti farmaceutski pripravci s fiksnom dozom koji sadrže irbesartan i amlodipin, njihova priprava i terapijska primjena - Google Patents
Äśvrsti farmaceutski pripravci s fiksnom dozom koji sadrže irbesartan i amlodipin, njihova priprava i terapijska primjena Download PDFInfo
- Publication number
- HRP20131088T1 HRP20131088T1 HRP20131088AT HRP20131088T HRP20131088T1 HR P20131088 T1 HRP20131088 T1 HR P20131088T1 HR P20131088A T HRP20131088A T HR P20131088AT HR P20131088 T HRP20131088 T HR P20131088T HR P20131088 T1 HRP20131088 T1 HR P20131088T1
- Authority
- HR
- Croatia
- Prior art keywords
- irbesartan
- amlodipine
- preparation
- preparation according
- tablet
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims 14
- 239000007787 solid Substances 0.000 title claims 7
- 239000000203 mixture Substances 0.000 title claims 6
- 229940043094 irbesartan and amlodipine Drugs 0.000 title claims 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 claims 11
- 239000002947 C09CA04 - Irbesartan Substances 0.000 claims 10
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims 10
- 229960002198 irbesartan Drugs 0.000 claims 10
- 229960004005 amlodipine besylate Drugs 0.000 claims 7
- 239000000314 lubricant Substances 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims 5
- 229960000528 amlodipine Drugs 0.000 claims 3
- 239000008187 granular material Substances 0.000 claims 3
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- 239000000480 calcium channel blocker Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000012535 impurity Substances 0.000 claims 2
- 239000008101 lactose Substances 0.000 claims 2
- 239000008183 oral pharmaceutical preparation Substances 0.000 claims 2
- 239000002356 single layer Substances 0.000 claims 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000007931 coated granule Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 238000009097 single-agent therapy Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Claims (15)
1. Stabilni čvrsti oralni farmaceutski pripravak s fiksnom dozom u obliku jednoslojne tablete koja sadrži irbesartan, amlodipin-besilat i farmaceutski prihvatljive pomoćne tvari, naznačen time što je irbesartan fizički odvojen od amlodipin-besilata i što je irbesartan u obliku obloženih granula uklopljen u ekstragranularni matriks koji sadrži amlodipin-besilat.
2. Pripravak u skladu s patentnim zahtjevom 1, naznačen time što je tableta obložena filmom.
3. Pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 2, naznačen time što irbesartan čini između 20% i 70%, težinski, od ukupnog pripravka.
4. Pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što amlodipin-besilat čini između 1% i 20%, težinski, od ukupnog pripravka.
5. Pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen timen što farmaceutski prihvatljive pomoćne tvari se bira iz skupine koju čine razrjeđivač, sredstvo za raspadanje, sredstvo protiv prijanjanja, vezivo, mazivo i njihova smjesa.
6. Pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što navedeni čvrsti pripravak ne sadrži laktozu.
7. Čvrsti pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time se što količina irbesartana kreće između 150 mg i 300 mg od ukupne težine tablete, po mogućnosti 300 mg ili 150 mg.
8. Čvrsti pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što se količina amlodipin-besilata kreće između 5mg i 10 mg od ukupne težine tablete, po mogućnosti 7 mg ili 14 mg.
9. Čvrsti pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 8 u obliku tablete, naznačen time što je ukupna težina tablete između 400 mg i 600 mg, po mogućnosti 500 mg.
10. Pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time što sadrži manje od 1,50% (tež./tež.) od ukupnih nečistoća za amlodipin i manje od 0,50% (tež./tež.) od ukupnih nečistoća za irbesartan nakon 6 mjeseci na 40 °C/75% relativne vlažnosti.
11. Postupak priprave stabilnog oralnog farmaceutskog pripravka u obliku jednoslojne tablete koja sadrži irbesartan i amlodipin-besilat, naznačen time što se postupak sastoji u koracima:
i) granuliranja irbesartana i jedne ili više farmaceutski prihvatljivih pomoćnih tvari, s vodenom otopinom koja sadrži vezivo, kako bi se dobilo granule;
ii) sušenja granula;
iii) odvojenog miješanja amlodipin-besilata s farmaceutski prihvatljivim pomoćnim tvarima;
iv) miješanje granula koje sadrže irbesartan iz koraka ii) sa smjesom koja sadrži amlodipin-besilat iz koraka iii);
v) dodavanja maziva u smjesu iz koraka iv); izborno nakon koraka prije dodavanja maziva; i
vi) komprimiranja smjese u tablete.
12. Postupak u skladu s patentnim zahtjevom 11, naznačen time što skupina farmaceutski prihvatljivih pomoćnih tvari upotrijebljenih u koraku i) i iii) postupka ne sadrži laktozu.
13. Postupak u skladu s bilo kojim od patentnih zahtjeva 11 do 12, naznačen time što se korak prije dodavanja maziva sastoji u miješanju smjese iz koraka iv) u trajanju od 10 do 25 minuta, po mogućnosti 20 minuta prije provođenja koraka dodavanja maziva.
14. Upotreba irbesartana i amlodipin-besilata u proizvodnji medikamenta za liječenje hipertenzije, naznačena time što je navedeni medikament u stabilnom čvrstom pripravku s fiksnom dozom u skladu s bilo kojim od patentnih zahtjeva 1 do 10.
15. Upotreba u skladu s patentnim zahtjevom 14, naznačena time što predstavlja liječenje pacijenata s hipertenzijom koja nije pod dovoljnom kontrolom amlodipinom kao monoterapijom blokatorom kalcijskih kanala (CCB) ili irbesartanom kao antagonistom receptora angiotenzina II (ARB).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1341DE2009 | 2009-06-30 | ||
| PCT/IB2009/007027 WO2011001202A1 (en) | 2009-06-30 | 2009-09-17 | Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20131088T1 true HRP20131088T1 (hr) | 2013-12-20 |
Family
ID=41460800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20131088AT HRP20131088T1 (hr) | 2009-06-30 | 2013-11-14 | Äśvrsti farmaceutski pripravci s fiksnom dozom koji sadrže irbesartan i amlodipin, njihova priprava i terapijska primjena |
Country Status (40)
| Country | Link |
|---|---|
| US (1) | US9173848B2 (hr) |
| EP (1) | EP2448561B1 (hr) |
| JP (1) | JP5763063B2 (hr) |
| KR (1) | KR101667081B1 (hr) |
| CN (2) | CN106176745A (hr) |
| AR (1) | AR077284A1 (hr) |
| AU (1) | AU2009349125B2 (hr) |
| BR (1) | BRPI0925315B8 (hr) |
| CA (1) | CA2766884C (hr) |
| CL (1) | CL2011003371A1 (hr) |
| CO (1) | CO6480972A2 (hr) |
| CR (1) | CR20110704A (hr) |
| CY (1) | CY1114933T1 (hr) |
| DK (1) | DK2448561T3 (hr) |
| DO (1) | DOP2011000406A (hr) |
| EA (1) | EA021317B1 (hr) |
| EC (1) | ECSP11011559A (hr) |
| ES (1) | ES2435240T3 (hr) |
| GT (1) | GT201100337A (hr) |
| HK (1) | HK1169309A1 (hr) |
| HR (1) | HRP20131088T1 (hr) |
| IL (1) | IL217229A (hr) |
| MA (1) | MA33463B1 (hr) |
| MX (1) | MX2011014005A (hr) |
| MY (1) | MY152951A (hr) |
| NI (1) | NI201100227A (hr) |
| NZ (1) | NZ597317A (hr) |
| PE (1) | PE20121131A1 (hr) |
| PL (1) | PL2448561T3 (hr) |
| PT (1) | PT2448561E (hr) |
| RS (1) | RS53087B (hr) |
| SG (1) | SG177426A1 (hr) |
| SI (1) | SI2448561T1 (hr) |
| SM (1) | SMT201400011B (hr) |
| TN (1) | TN2011000651A1 (hr) |
| TW (1) | TWI476191B (hr) |
| UA (1) | UA103688C2 (hr) |
| UY (1) | UY32749A (hr) |
| WO (1) | WO2011001202A1 (hr) |
| ZA (1) | ZA201109541B (hr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6041591B2 (ja) * | 2011-09-13 | 2016-12-14 | 大日本住友製薬株式会社 | イルベサルタンとアムロジピンまたはその塩を含有する安定化された医薬組成物 |
| KR20150078215A (ko) * | 2013-12-30 | 2015-07-08 | (주) 드림파마 | 에프로사탄 및 암로디핀을 포함하는 복합제제 및 이의 제조방법 |
| CN104758283A (zh) * | 2014-01-02 | 2015-07-08 | 江苏吉贝尔药业有限公司 | 一种抗高血压制剂 |
| CN104000821B (zh) * | 2014-06-02 | 2020-06-19 | 浙江华海药业股份有限公司 | 含有替米沙坦和苯磺酸氨氯地平的口服双层片剂及其制备方法 |
| EP3244880A1 (en) * | 2015-01-12 | 2017-11-22 | Ilko Ilaç Sanayi Ve Ticaret Anonim Sirketi | A stable bilayer pharmaceutical tablet compositions comprising fixed dose of irbesartan and amlodipine |
| JP6737060B2 (ja) * | 2015-09-11 | 2020-08-05 | ニプロ株式会社 | イルベサルタンを含有する医薬組成物の製造方法 |
| US10350171B2 (en) | 2017-07-06 | 2019-07-16 | Dexcel Ltd. | Celecoxib and amlodipine formulation and method of making the same |
| CN111212641A (zh) * | 2017-10-13 | 2020-05-29 | 联合化学工业公司实验室有限公司 | 阿普斯特的药物组合物 |
| CN108578404B (zh) * | 2018-04-28 | 2020-04-28 | 广州白云山天心制药股份有限公司 | 一种含厄贝沙坦和氨氯地平的药用组合物及其制备方法 |
| GR1010320B (el) * | 2021-08-04 | 2022-10-11 | Win Medica Φαρμακευτικη Ανωνυμη Εταιρεια, | Στερεες φαρμακοτεχνικες μορφες ιρβεσαρτανης, υδροχλωροθειαζιδης και αμλοδιπινης |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5994348A (en) * | 1995-06-07 | 1999-11-30 | Sanofi | Pharmaceutical compositions containing irbesartan |
| TW442301B (en) * | 1995-06-07 | 2001-06-23 | Sanofi Synthelabo | Pharmaceutical compositions containing irbesartan |
| JP4829115B2 (ja) * | 2003-10-10 | 2011-12-07 | ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 選択的ｉ１イミダゾリンレセプターアゴニストおよびアンギオテンシンｉｉレセプターブロッカーを含有する医薬組成物 |
| US20050187262A1 (en) * | 2004-01-12 | 2005-08-25 | Grogan Donna R. | Compositions comprising (S)-amlodipine and an angiotensin receptor blocker and methods of their use |
| BE1015867A3 (fr) | 2004-01-22 | 2005-10-04 | Sonaca Sa | Ensemble de bord d'attaque d'un element de voilure d'aeronef et element de voilure equipee d'au moins un tel ensemble. |
| US20050250838A1 (en) * | 2004-05-04 | 2005-11-10 | Challapalli Prasad V | Formulation for sustained delivery |
| CN100364532C (zh) * | 2004-09-30 | 2008-01-30 | 江苏恒瑞医药股份有限公司 | 包含氨氯地平和血管紧张素ⅱ受体抑制剂的组合物 |
| ATE451925T1 (de) * | 2004-10-06 | 2010-01-15 | Eisai R&D Man Co Ltd | Medizinische zusammensetzung, verfahren zu ihrer herstellung und verfahren zur stabilisierung einer dihydropyridin-verbindung in einer medizinischen zusammensetzung |
| EA013053B1 (ru) * | 2004-11-05 | 2010-02-26 | Бёрингер Ингельхайм Интернациональ Гмбх | Двуслойная таблетка, содержащая телмисартан и амлодипин |
| WO2007001067A2 (en) * | 2005-06-27 | 2007-01-04 | Daiichi Sankyo Company, Limited | Solid dosage form comprising an angiotensin ii receptor antagonist and a calcium channel blocker |
| WO2007001065A2 (en) * | 2005-06-27 | 2007-01-04 | Daiichi Sankyo Company, Limited | Method for the preparation of a wet granulated drug product |
| CN101247832B (zh) * | 2005-06-27 | 2011-12-28 | 第一三共株式会社 | 含有血管紧张素ⅱ受体拮抗剂和钙通道阻断剂的药物制剂 |
| KR100888131B1 (ko) * | 2006-10-10 | 2009-03-11 | 한올제약주식회사 | 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제 |
| KR101247583B1 (ko) * | 2006-12-08 | 2013-03-26 | 한미사이언스 주식회사 | 암로디핀 또는 이의 약제학적 허용가능한 염, 및 로자탄또는 이의 약제학적 허용가능한 염을 함유하는 약제학적조성물 |
| TWI402083B (zh) * | 2006-12-26 | 2013-07-21 | Daiichi Sankyo Co Ltd | 固形製劑及其安定化方法 |
-
2009
- 2009-09-17 PE PE2011002177A patent/PE20121131A1/es not_active Application Discontinuation
- 2009-09-17 AU AU2009349125A patent/AU2009349125B2/en active Active
- 2009-09-17 EP EP09744185.1A patent/EP2448561B1/en active Active
- 2009-09-17 JP JP2012518134A patent/JP5763063B2/ja active Active
- 2009-09-17 ES ES09744185T patent/ES2435240T3/es active Active
- 2009-09-17 SI SI200930773T patent/SI2448561T1/sl unknown
- 2009-09-17 UA UAA201200881A patent/UA103688C2/uk unknown
- 2009-09-17 MY MYPI20116321 patent/MY152951A/en unknown
- 2009-09-17 PL PL09744185T patent/PL2448561T3/pl unknown
- 2009-09-17 KR KR1020127002271A patent/KR101667081B1/ko active IP Right Grant
- 2009-09-17 EA EA201270087A patent/EA021317B1/ru not_active IP Right Cessation
- 2009-09-17 DK DK09744185.1T patent/DK2448561T3/da active
- 2009-09-17 MA MA34578A patent/MA33463B1/fr unknown
- 2009-09-17 PT PT97441851T patent/PT2448561E/pt unknown
- 2009-09-17 WO PCT/IB2009/007027 patent/WO2011001202A1/en active Application Filing
- 2009-09-17 CA CA2766884A patent/CA2766884C/en active Active
- 2009-09-17 CN CN201610569660.0A patent/CN106176745A/zh active Pending
- 2009-09-17 BR BRPI0925315A patent/BRPI0925315B8/pt active IP Right Grant
- 2009-09-17 RS RS20130494A patent/RS53087B/en unknown
- 2009-09-17 SG SG2011097276A patent/SG177426A1/en unknown
- 2009-09-17 MX MX2011014005A patent/MX2011014005A/es active IP Right Grant
- 2009-09-17 CN CN2009801611743A patent/CN102573804A/zh active Pending
- 2009-09-17 NZ NZ597317A patent/NZ597317A/en unknown
- 2009-09-17 US US13/381,534 patent/US9173848B2/en active Active
-
2010
- 2010-06-29 AR ARP100102311A patent/AR077284A1/es not_active Application Discontinuation
- 2010-06-29 TW TW099121306A patent/TWI476191B/zh active
- 2010-06-30 UY UY0001032749A patent/UY32749A/es not_active Application Discontinuation
-
2011
- 2011-12-20 TN TNP2011000651A patent/TN2011000651A1/en unknown
- 2011-12-21 CR CR20110704A patent/CR20110704A/es unknown
- 2011-12-22 NI NI201100227A patent/NI201100227A/es unknown
- 2011-12-23 ZA ZA2011/09541A patent/ZA201109541B/en unknown
- 2011-12-26 DO DO2011000406A patent/DOP2011000406A/es unknown
- 2011-12-27 GT GT201100337A patent/GT201100337A/es unknown
- 2011-12-27 IL IL217229A patent/IL217229A/en active IP Right Grant
- 2011-12-28 EC EC2011011559A patent/ECSP11011559A/es unknown
- 2011-12-29 CO CO11180686A patent/CO6480972A2/es not_active Application Discontinuation
- 2011-12-30 CL CL2011003371A patent/CL2011003371A1/es unknown
-
2012
- 2012-10-08 HK HK12109829.4A patent/HK1169309A1/xx unknown
-
2013
- 2013-11-14 CY CY20131101010T patent/CY1114933T1/el unknown
- 2013-11-14 HR HRP20131088AT patent/HRP20131088T1/hr unknown
-
2014
- 2014-01-24 SM SM201400011T patent/SMT201400011B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20131088T1 (hr) | Äśvrsti farmaceutski pripravci s fiksnom dozom koji sadrže irbesartan i amlodipin, njihova priprava i terapijska primjena | |
| CA2601955A1 (en) | Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer | |
| RU2005114612A (ru) | Композиция, ингибирующая секрецию кислоты в желудке | |
| RU2016152167A (ru) | Фармацевтические препараты, содержащие производные нитрокатехина, и способы их получения | |
| EP2676660A1 (en) | Compositions preventing hypertension comprising soluplus | |
| KR20160058763A (ko) | 암로디핀 및 발사르탄를 함유하는 안정적인 약제학적 조성물 | |
| RU2016117186A (ru) | Комбинированная композиция, содержащая тадалафил и амлодипин | |
| TWI586353B (zh) | Pharmaceutical preparations containing calcium antagonists and angiotensin II receptor antagonists | |
| JP5790965B2 (ja) | カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤の製造方法 | |
| CN106983726B (zh) | 阿齐沙坦片及其制备方法 | |
| JP2015120758A5 (hr) | ||
| CN101416966A (zh) | 一种治疗高血压的药物组合物 | |
| EP3236950B1 (en) | Pharmaceutical composition comprising candesartan or pharmaceutically acceptable salts or esters thereof and amlodipine or pharmaceutically acceptable salts thereof | |
| WO2019135691A1 (en) | A stable mono-layer solid dosage form containing combination of two active ingredients | |
| CN101756977A (zh) | 阿折地平的缓释制剂及其制备方法 | |
| CN101849940B (zh) | 一种治疗高血压的药物组合物 | |
| JP2010509293A5 (hr) | ||
| US20110206761A1 (en) | Stable dosage forms of antihypertensive agents | |
| EP3244880A1 (en) | A stable bilayer pharmaceutical tablet compositions comprising fixed dose of irbesartan and amlodipine | |
| EP2519229A2 (en) | New pharmaceutical dosage form for the treatment of gastric acid-related disorders | |
| WO2010134097A2 (en) | Stable pharmaceutical compositions of olanzapine and process for their preparation | |
| CA2988267A1 (en) | Extended release capecitabine capsules | |
| Sanghi et al. | FORMULATION AND EVALUTATION OF DUAL RELEASE MULTIPLE UNIT TABLET FORMULATION | |
| PL218490B1 (pl) | Postać farmaceutyczna zawierająca terapeutycznie skuteczną ilość antagonisty receptorów AT<sub>1</sub> angiotensyny II - losartanu potasu oraz sposób jej wytwarzania | |
| PL223223B1 (pl) | Sposób wytwarzania tabletki o zwiększonej dostępności farmaceutycznej worykonazolu |